Noncovalent BTK Inhibitors in CLL
Recommendations for applying information from clinical trials presented at oncology and hematology conferences in 2021 into routine clinical practice when managing patients with chronic lymphocytic leukemia.
Read More
Fixed-Duration Therapy in Relapsed/Refractory CLL: Ibrutinib Plus Venetoclax
Considerations for treating patients with relapsed/refractory chronic lymphocytic leukemia with the combination of ibrutinib and venetoclax.
Read More
BTK Inhibitors as Frontline Therapy for CLL
The rationale for using Bruton tyrosine kinase inhibitors, such as the first-generation option, ibrutinib, as first-line treatment for chronic lymphocytic leukemia.
Read More
Dr. Lamanna Discusses the MURANO Trial in CLL
January 2nd 2019Nicole Lamanna, MD, associate professor of medicine, Hematologic Malignancies Section, Division of Hematology/Oncology, NewYork-Presbyterian/Columbia University Medical Center, discusses the MURANO trial in patients with chronic lymphocytic leukemia.
Read More
Dr. Lamanna on Incorporating Novel and Traditional Therapies in CLL
May 15th 2015Nicole Lamanna, MD, Associate Professor of Clinical Medicine, Columbia University Medical Center, discusses incorporating novel therapies into the standard treatment paradigm for patients with chronic lymphocytic leukemia (CLL).
Read More